However, for monitoring treatment response in patients with MM, sFLC is recommended only for those patients in whom there is no “measurable disease” using electrophoretic methods (serum M-protein <1 g/dL by SPE and urine M-protein <200 mg/24 h by UPE) and for determining the stringent complete response (sCR) [12,43,44]. The gene discussed is MYOM2; the disease is Miyoshi myopathy.